Argent Biopharma Limited has released a press release.
CimetrA Phase IIb Clinical Trial Results
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Argent Biopharma
- Argent BioPharma Expands Pipeline with Promising Drug CimetrA®
- Exclusive Agreement for Malta Manufacturing Facility
- Strategic Manufacturing Partnership with ECCPharm Limited
- Half Year Accounts
- Corporate Update - Board Change
Later from Argent Biopharma
- CannEpil Receives Approval for Prescription in Germany
- Strategic Collaboration Agreement for Malta Facility
- Strategic Agreement to Enhance Cannabinoid Development
- Argent BioPharma Enters Germany - Europe's Largest Market
- EU-GMP Cannabinoid API Supplied for Epilepsy in Slovenia
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma